Neisseria meningitidis Infections Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 70 pages | ID: N0316350ADD7EN
VPAResearch

Abstracts

Neisseria meningitidis Infections Drug pipeline report- 2020 is an annual R&D review of Neisseria meningitidis Infections pipeline candidates. The report presents the current status of all major Neisseria meningitidis Infections therapeutic compounds. Detailed insights into Neisseria meningitidis Infections pipeline development, current status, companies, drug profiles and Neisseria meningitidis Infections preclinical and clinical trials are included.

2020 Neisseria meningitidis Infections Pipeline Market Insights
Neisseria meningitidis Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Neisseria meningitidis Infections therapies, pipeline by phase and others are included.

Neisseria meningitidis Infections pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Neisseria meningitidis Infections Therapeutic Drug candidates
Both active and inactive Neisseria meningitidis Infections pipeline drug candidates are included in the report

Neisseria meningitidis Infections Clinical Trials and preclinical Studies
Neisseria meningitidis Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Neisseria meningitidis Infections pipeline market developments
Neisseria meningitidis Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Neisseria meningitidis Infections pipeline companies in active development
The report analyzes Neisseria meningitidis Infections pipeline of the below companies-

Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, GlaxoSmithKline Plc, ImmunoBiology Ltd, JN-International Medical Corporation, Johnson & Johnson, MGB Biopharma Ltd, Neoculi Pty Ltd, Panacea Biotec Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Tianjin CanSino Biotechnology Inc, Wellstat Vaccines LLC

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
14 Companies investing in Neisseria meningitidis Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Neisseria meningitidis Infections pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE MARKET INSIGHTS, 2020

1.1 Neisseria meningitidis Infections Disease Overview
1.2 Neisseria meningitidis Infections Drug Pipeline Snapshot, 2020
  1.2.1 Neisseria meningitidis Infections Pipeline Drugs by Phase
  1.2.2 Neisseria meningitidis Infections Pipeline Drugs by Company
  1.2.3 Neisseria meningitidis Infections Pipeline Drugs by Mechanism of Action
  1.2.4 Neisseria meningitidis Infections Pipeline Drugs by Route of Administration

2. NEISSERIA MENINGITIDIS INFECTIONS COMPANY WISE PIPELINE DETAILS

Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Biological E Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
GlaxoSmithKline Plc Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
ImmunoBiology Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
JN-International Medical Corporation Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Johnson & Johnson Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
MGB Biopharma Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Neoculi Pty Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Panacea Biotec Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Pfizer Inc Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sanofi Pasteur SA Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Serum Institute of India Ltd Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Tianjin CanSino Biotechnology Inc Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details
Wellstat Vaccines LLC Neisseria meningitidis Infections Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. NEISSERIA MENINGITIDIS INFECTIONS DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. NEISSERIA MENINGITIDIS INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts